The two studies presented at the meeting include:
Effect of Obesity on Symptom Resolution in Patients with Gastroesophageal Reflux Disease (GERD)
2007 ACG Presidential Poster Award Recipient
Poster Presentation, Sunday, October 14, 2007
Exhibit Hall B, Pennsylvania Convention Center: Poster #30
Is Obesity the Cause of Reduced Healing Rates in Advanced Grades of Erosive Esophagitis?
Poster Presentation, Monday, October 15, 2007
Exhibit Hall B, Pennsylvania Convention Center: Poster #594
About NEXIUM(R) (esomeprazole magnesium)
NEXIUM, launched in the U.S. in 2001, is approved for the treatment of heartburn and other symptoms associated with GERD, as well as for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of NEXIUM may be considered. NEXIUM is indicated to maintain symptom resolution and healing of erosive esophagitis. Controlled studies do not extend beyond 6 months.
Common side effects with NEXIUM include headache, diarrhea, and abdominal pain. Symptom relief does not rule out other serious stomach conditions.
AstraZeneca is committed to helping people get the medicines they need. In 2006, 97,614 NEXIUM patients were provided patient assistance through AstraZeneca programs, which equates to patient savings of $105M.
Nationwide, the majority of people with prescription coverage can get NEXIUM for less than a dollar a day, based on the national average co-pay.(6) Individual costs may vary.
For more information about NEXIUM, please visit: http://www.nexium-us.com.
AstraZeneca is a major international healthcare business engaged in the
research, development, manufacture and marketing of prescription
Copyright©2007 PR Newswire.
All rights reserved